TargetMol中国(陶术生物) 公司信息
公司名称:
TargetMol中国(陶术生物)
电话:
-
电子邮件:
marketing@targetmol.com
国籍:
中国
网址:
https://www.targetmol.cn/
产品总数:
28118
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
公司提供产品列表
Felzartamab;TJ-202|||MOR-03087|||MOR-202
菲泽妥单抗;TJ-202|||MOR-03087|||MOR-202
2197112-39-1
CCR1/5/8 activator 1;
化合物 CCR1/5/8 activator 1;
4771-50-0
tert-Butyl5-bromo-1H-indole-1-carboxylate;N-Boc-5-bromoindole
N-叔丁氧羰基-5-溴吲哚;N-Boc-5-bromoindole
182344-70-3
BRD4-IN-4;
化合物BRD4-IN-4;
304685-40-3
Ulocuplumab;BMS 936564|||MDX 1338
乌洛鲁单抗;BMS 936564|||MDX 1338
1375830-34-4
Garetosmab;
加托索单抗;REGN 2477
2097125-54-5
Bersanlimab;BI-505
Bersanlimab单抗;BI-505
1987854-08-9
Itepekimab;REGN-3500|||SAR-440340
单抗Itepekimab;REGN-3500|||SAR-440340
2226742-52-3
Palivizumab;Synagis|||MEDI 493
帕利珠单抗;Synagis|||MEDI 493
188039-54-5
2-aminobenzo[d]thiazol-6-ol;
2-氨基-6-羟基苯并噻唑;
26278-79-5
Sibrotuzumab;BIBH 1|||Anti-Human FAP Recombinant Antibody
西罗珠单抗;BIBH 1|||Anti-Human FAP Recombinant Antibody
216669-97-5
Mannan;
甘露聚糖;
9036-88-8
Icrucumab;LY 3012212|||IMC-18F1
艾芦库单抗;LY 3012212|||IMC-18F1
1024603-92-6
Flanvotumab;20D7S|||IMC 20D7S
夫兰妥单抗;20D7S|||IMC 20D7S
1188277-05-5
Tafasitamab;MOR00208|||XmAb5574|||Tafasitamab-cxix
塔法西他单抗;MOR00208|||XmAb5574|||Tafasitamab-cxix
1422527-84-1
Tezepelumab;Tezepelumab-ekko|||MEDI 19929|||AMG 157
替西伐单抗;Tezepelumab-ekko|||MEDI 19929|||AMG 157
1572943-04-4
Belantamab;GSK2857914
贝兰妥单抗;GSK2857914
2061894-48-0
Sibeprenlimab;
Sibeprenlimab单抗;VIS649|||VIS-649
2382896-07-1
Siplizumab;MEDI-507
西利珠单抗;MEDI-507
288392-69-8
Concizumab;mAb 2021|||NN 7415
康赛珠单抗;mAb 2021|||NN 7415
1312299-39-0
Tesidolumab;LFG316
特度鲁单抗;LFG316
1531594-08-7
Ascrinvacumab;PF-03446962
阿伐苏单抗;PF-03446962
1463459-96-2
Xentuzumab;BI 836845
珍妥珠单抗;BI 836845
1417158-65-6
Narsoplimab;OMS 721
纳索利单抗;OMS 721
2108782-45-0
Spesolimab;BI 655130
司柏索利单抗;BI 655130
2097104-58-8
Nimacimab;JNJ 2463|||RYI-018
尼迈西单抗;JNJ 2463|||RYI-018
2098636-09-8
Nidanilimab;
尼达利单抗;CAN04
2171061-85-9
Praluzatamab;
普罗妥单抗;
2145109-70-0
Clesrovimab;MK-1654
单抗Clesrovimab;MK-1654
2429913-18-6
HDAC-IN-57;
化合物HDAC-IN-57;
2716217-79-5
UK 088800;
化合物UK 088800;5-(2-乙氧苯基)-1-甲基-3-丙基-1,6-二氢-7H-吡唑并[4,3-D]嘧啶-7-酮
139756-21-1
Belimumab;LymphoStat B
贝利尤单抗;LymphoStat B
356547-88-1
Teneliximab;Chi220|||Anti-Human CD40 Recombinant Antibody|||BMS 224819
化合物Teneliximab;Chi220|||Anti-Human CD40 Recombinant Antibody|||BMS 224819
299423-37-3
Ganitumab;AMG 479
加尼妥单抗;AMG 479
905703-97-1
Tisotumab;1E10|||1.00E+10
替索妥单抗;1E10|||1.00E+10
1418628-81-5
Talacotuzumab;CSL 362|||JNJ 56022473
塔妥珠单抗;CSL 362|||JNJ 56022473
1826831-79-1
Ragifilimab;INCAGN-01876|||INCAGN-1876|||CM-701
拉格芙利单抗;INCAGN-01876|||INCAGN-1876|||CM-701
2207590-51-8
TV 3279;
化合物TV 3279;
209394-29-6
Sonepcizumab;LT 1009
Sonepcizumab单抗;LT 1009
1031360-18-5
(Iso)-BMT-124110 Formate;(R)-N-(8-((2-amino-2,4-dimethylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)acetamide Formate(1679370-98-9 Free base)
化合物 (Iso)-BMT-124110 Formate;(R)-N-(8-((2-amino-2,4-dimethylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)acetamide Formate(1679370-98-9 Free base)
Sodium 2-oxopropanoate;Sodium pyruvate
丙酮酸钠;Sodium pyruvate|||丙酮酸钠
113-24-6
2-Amino-6-bromopyridine;
2-氨基-6-溴吡啶;
19798-81-3
FG-3019;
化合物 FG-3019;
946415-13-0
Carotuximab;
卡妥昔单抗;DE-122|||TRC105
1268714-50-6
Elezanumab;AE12-1Y-QL|||ABT-555
依来努单抗;AE12-1Y-QL|||ABT-555
1791416-49-3
Tomaralimab;OPN-305
托拉利单抗;OPN-305
1449294-76-1
Spartalizumab;PDR001
斯巴达珠单抗;PDR001
1935694-88-4
Enapotamab;
Enapotamab单抗;
1912423-61-0
Cobolimab;
考伯利单抗;TSR-022|||GSK4069889
2022215-65-0
Garadacimab;CSL312
加达西单抗;CSL312
2162134-62-3
Latozinemab;GSK-4527223|||AL-001
单抗Latozinemab;GSK-4527223|||AL-001
2376132-27-1
Theralizumab;
Theralizumab单抗;TGN1412|||TAB-08|||TABO8
906068-56-2
Clivatuzumab;
克利妥珠单抗;
1622075-09-5
Abciximab;C7E3
阿昔单抗;C7E3
143653-53-6
PLH1215;
化合物 PLH1215;
1332084-64-6
AB21 HCl;
AB21盐酸盐;
ACEPROMAZINE MALEATE;
乙酰丙嗪马来酸酯;
3598-37-6
D-Ribose 5-phosphate disodium dihydrate;
D-Ribose 5-phosphate 钠盐水合物;
207671-46-3
Suptavumab;REGN2222
舒他伏单抗;REGN2222
1629615-23-1
Ianalumab;VAY-736
伊利尤单抗;VAY-736
1929549-92-7
Quetmolimab;E-6011|||KANAb 001
奎莫利单抗;E-6011|||KANAb 001
2084037-83-0
Telazorlimab;ISB-830|||GBR-830
特拉佐利单抗;ISB-830|||GBR-830
2126777-87-3
Anetumab;
阿奈妥单抗;
1954758-84-9
Ordesekimab;AMG 714|||PRV-015
奥司奇单抗;AMG 714|||PRV-015
879293-15-9
ACHE Inhibitor 12;
化合物 ACHE Inhibitor 12;
66309-83-9
Aducanumab;
阿杜那单抗;BIIB037
1384260-65-4
Butylboronicacid;
正丁基硼酸;
4426-47-5
Andecaliximab;GS-5745
Andecaliximab单抗;GS-5745
1518996-49-0
Plozalizumab;
洛扎利珠单抗;MLN-1202
1610761-46-0
Leronlimab;
乐利单抗;PRO 140
674782-26-4
Nirsevimab;
尼塞韦单抗;MEDI8897
1989556-22-0
Vofatamab;RG-7444|||B-701|||MFGR-1877S
沃凡妥单抗;RG-7444|||B-701|||MFGR-1877S
1312305-12-6
Astegolimab;RG 6149|||MSTT 1041A
艾特利单抗;RG 6149|||MSTT 1041A
2173054-79-8
Nadecnemab;REGN-5069
Nadecnemab单抗;REGN-5069
2377679-19-9
MyD88-IN-1;
化合物MyD88-IN-1;
2911609-80-6
Ramiprilat;
雷米普利;
87269-97-4
Efalizumab;Hu1124|||HU 1124
依法利珠单抗;Hu1124|||HU 1124
214745-43-4
GSNKGAIIGLM(131602-53-4(free base));Amyloid beta-peptide(25-35)
BETA-淀粉样蛋白片断25-35;Amyloid beta-peptide(25-35)|||BETA-淀粉样蛋白片断25-35
131602-53-4
Patritumab;
帕曲妥单抗;U3-1287|||AMG-888
1262787-83-6
Oxelumab;Ro 49-89991|||R 4930|||huMAb OX 40L
奥塞芦单抗;Ro 49-89991|||R 4930|||huMAb OX 40L
1186098-83-8
Abrezekimab;UCB4144|||VR 942
阿泽奇单抗;UCB4144|||VR 942
2043952-59-4
Vixarelimab;
单抗Vixarelimab;RG-6536|||RO-7622888|||KPL-716
2243320-83-2
Burfiralimab;hzVSF-v13
化合物 Burfiralimab;hzVSF-v13
2460809-80-5
icFSP1;
化合物IcFSP1;
1115910-36-5
PLH2058;
化合物 PLH2058;
2525206-41-9
Lexatumumab;ETR2-ST01|||DR5 mAB|||HGS-ETR 2
来沙木单抗;ETR2-ST01|||DR5 mAB|||HGS-ETR 2
845816-02-6
Urelumab;BMS-663513|||BMS-66513
乌瑞芦单抗;BMS-663513|||BMS-66513
934823-49-1
Ravulizumab;ALXN1210
雷夫利珠单抗;ALXN1210
1803171-55-2
Otilimab;GSK 3196165|||MOR103
Otilimab单抗;GSK 3196165|||MOR103
1638332-55-4
Vorsetuzumab;SGN-70
沃瑟妥珠单抗;SGN-70
1165740-62-4
Osocimab;BAY 1213790
奥索西单抗;BAY 1213790
2056878-75-0
Cinpanemab;BIIB054
辛帕奈单抗;BIIB054
2094516-02-4
Lecanemab;BAN-2401
仑卡奈单抗;BAN-2401
1260393-98-3
DSPE-NHS;
化合物 DSPE-NHS;
1383932-86-2
5-Nitro-1,10-phenanthroline;5-NP
5-硝基-1,10-菲咯啉;5-NP|||5-硝基-1,10-菲咯啉
4199-88-6
Siltuximab;CNTO-328
司妥昔单抗;CNTO-328
541502-14-1
Erenumab;AMG-334
厄瑞努单抗;AMG-334
1582205-90-0
Donanemab;
化合物 Donanemab;
1931944-80-7
Petosemtamab;MCLA 158
派森妥单抗;MCLA 158
2213450-26-9
Talquetamab;JNJ-64407564|||JNJ-7564
塔奎妥单抗;JNJ-64407564|||JNJ-7564
2226212-40-2
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
Copyright 2007© ChemicalBook. All rights reserved.